Abstract:BACKGROUND:Metformin, which is widely used as an antidiabetic agent, has recently been reported to reduce cancer risk and improve prognosis in certain malignancies. However, the specific mechanisms underlying the effect of metformin on the development and progression of several cancers including oral squamous cell carcinoma (OSCC) remain unclear. In the present study, we investigated the effects of metformin on OSCC cells in vitro and in vivo.METHODS:OSCC cells treated with or without metformin were counted using a hemocytometer. The clonogenic ability of OSCC cells after metformin treatment was determined by colony formation assay. Cell cycle progression and apoptosis were assessed by flow cytometry, and the activation of related signaling pathways was examined by immunoblotting. The in vivo anti-tumor effect of metformin was examined using a xenograft mouse model. Immunohistochemistry and TUNEL staining were used to determine the expression of cyclin D1 and the presence of apoptotic cells in tumors from mice treated with or without metformin.RESULTS:Metformin inhibited proliferation in the OSCC cell lines CAL27, WSU-HN6 and SCC25 in a time- and dose-dependent manner, and significantly reduced the colony formation of OSCC cells in vitro. Metformin induced an apparent cell cycle arrest at the G0/G1 phase, which was accompanied by an obvious activation of the AMP kinase pathway and a strongly decreased activation of mammalian target of rapamycin and S6 kinase. Metformin treatment led to a remarkable decrease of cyclin D1, cyclin-dependent kinase (CDK) 4 and CDK6 protein levels and phosphorylation of retinoblastoma protein, but did not affect p21 or p27 protein expression in OSCC cells. In addition, metformin induced apoptosis in OSCC cells, significantly down-regulating the anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulating the pro-apoptotic protein Bax. Metformin also markedly reduced the expression of cyclin D1 and increased the numbers of apoptotic cells in vivo, thus inhibiting the growth of OSCC xenografts.CONCLUSIONS:Our data suggested that metformin could be a potential candidate for the development of new treatment strategies for human OSCC.

Metformin: A Promising Drug for Human Cancers (Review)

Repurposing old drugs for a new life：metformin shows promising in cancer care

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing

Metformin and Cancer: an Existing Drug for Cancer Prevention and Therapy (Review)

Metformin, an Old Drug, Brings a New Era to Cancer Therapy.

Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Anticancer mechanisms of metformin: A review of the current evidence

A Narrative Review: Repurposing Metformin as a Potential Therapeutic Agent for Oral Cancer

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models

Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Metformin: Current Clinical Applications in Nondiabetic Patients with Cancer

In Vitro and in Vivo Anti-Tumor Effect of Metformin As a Novel Therapeutic Agent in Human Oral Squamous Cell Carcinoma.

Metformin Targets Multiple Signaling Pathways in Cancer

Novel application of metformin combined with targeted drugs on anticancer treatment

Non-coding RNAs as potential targets in metformin therapy for cancer

Repurposing Metformin in hematologic tumor: State of art

Metformin: An Old Drug with New Applications